After a tough haul, John Lechleiter is stepping down at Eli Lilly
After steering Eli Lilly through a long R&D drought that leaves the pharma giant with some blockbuster drug prospects, Eli Lilly CEO John Lechleiter says it’s time to step aside.
Lechleiter said this morning that he will step down from the helm at the end of this year, making way for president David Ricks to move up to the top spot. And after a brief spell as executive chairman, he will leave the company next spring.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.